comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-27 21:54:57 - browse：87

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Researchers explore possible ties between long Covid, menopause

focus

WSS

STAT Summit: GSK CEO on pharma giant's new direction

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Why health workers in Gaza are injured or die at high rates

Why health workers in Gaza are injured or die at high rates

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Elevance PBM president out as customers face prescription chaos

hotspot

comprehensive

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: How a Chicago ER doctor tackles gun violence

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA struggles to regulate food additives, sometimes for decades

How one medical school became remarkably diverse

Data don't support strong claims for Covid

As demand for Covid shots wanes, Moderna seeks its next success

Senate committee scrutinizes Medicare Advantage brokers

The high cost of giving birth even with insurance

STAT Summit: GSK CEO on pharma giant's new direction

explore

Congress needs to close a vaccine

A new initiative will help leaders fight the next pandemic

Elevance PBM president out as customers face prescription chaos

Stopping antidepressants leads to symptoms for 1 in 6 patients

STAT Readout Newsletter: Today's biggest biotech updates

Eli Lilly’s Zepbound improved liver scarring in mid

entertainment

focus

hotspot

explore